^
    CANCER:

    Pancreatic Ductal Adenocarcinoma





    Show legend
    Group by Gene:
    Include preclinical:

    nivolumab
    pembrolizumab
    		0
    PD1 inhibitor
    PD1 inhibitor
    toripalimab-tpzi
    sintilimab
    1
    DNA synthesis inhibitor
    gemcitabine
    cisplatin + gemcitabine
    2
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    3
    PD-L1 inhibitor, MEK inhibitor
    avelumab + binimetinib
    4
    PARP inhibitor
    olaparib
    PARP inhibitor
    5
    PD-L1 inhibitor, Apoptosis stimulant
    atezolizumab + pelareorep
    6
    Gene transference, Thymidine kinase stimulant
    aglatimagene besadenovec
    7
    Topoisomerase I inhibitor
    irinotecan
    8
    ALK inhibitor
    alectinib
    crizotinib
    9
    KRAS G12C inhibitor
    adagrasib
    10
    CLDN18.2-targeted CAR-T immunotherapy
    CT041
    11
    CTLA4 inhibitor
    ipilimumab
    12
    Hyaluronidase stimulant
    PEGPH20
    13
    ERK2 inhibitor, ERK1 inhibitor
    BVD-523
    14
    IL1RAP inhibitor
    CAN04
    15
    HER2 inhibitor, HER3 inhibitor
    MCLA-128
    16
    RAS inhibitor
    RMC-6236
    17
    PD1 inhibitor, PARP inhibitor
    pembrolizumab + olaparib
    18
    MEK inhibitor, BRAF inhibitor, BRAF V600E inhibitor
    trametinib + vemurafenib
    19
    Multi-tyrosine kinase inhibitor
    anlotinib
    20
    PD1 inhibitor, MEK inhibitor
    pembrolizumab + trametinib
    21
    Telomerase inhibitor, HBsAg release inhibitor, Viral replication inhibitor
    tertomotide
    22
    DNA synthesis inhibitor, DNA cross linking agent, Thymidylate synthase inhibitor
    5-fluorouracil + oxaliplatin
    23
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    gemcitabine + capecitabine
    24
    NRP1 modulator, Capillary permeability modulator
    LSTA1
    25
    DNA synthesis inhibitor, Bcl2 inhibitor, Tubulin inhibitor
    gemcitabine + albumin-bound paclitaxel
    26
    CTLA4 inhibitor, PARP inhibitor
    ipilimumab + niraparib
    27
    CASP3 stimulant, Ornithine decarboxylase inhibitor, AMD1 inhibitor, PARP inhibitor
    SBP-101
    28
    Chemotherapy
    FOLFIRINOX
    29
    PTPN11 inhibitor, ERK inhibitor
    PTPN11 inhibitor + ERK inhibitor
    Hedgehog cell-signalling pathway inhibitor
    GANT1
    		30
    Hedgehog cell-signalling pathway inhibitor
    GANT61
    cyclopamine
    sonidegib
    31
    Immunotherapy
    Immunotherapy
    32
    Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor
    gemcitabine + paclitaxel
    33
    BET inhibitor, CDK inhibitor
    BET inhibitor + CDK inhibitor
    34
    B7-H3-targeted antibody-drug conjugate
    B7-H3-targeted antibody-drug conjugate
    35
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    afatinib
    36
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    37
    PD-L1 inhibitor, CTLA4 inhibitor
    durvalumab + tremelimumab
    38
    PD-L1 inhibitor, DNA synthesis inhibitor, CTLA4 inhibitor
    durvalumab + gemcitabine + tremelimumab
    39
    MEK inhibitor, BRAF inhibitor, MEK2 inhibitor, MEK1 inhibitor, BRAF V600E inhibitor
    vemurafenib + HL-085
    40
    KRAS G12D inhibitor
    MRTX1133
    RMC-9805
    41
    Thymidylate synthase inhibitor
    5-fluorouracil
    42
    Folate analog
    leucovorin calcium
    43
    TNKS inhibitor, PARP inhibitor
    JPI-547
    44
    KRAS G12D degrader
    ASP3082
    45
    c-MET-targeted antibody-drug conjugate, EGFR-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    DM005
    46
    KRAS G12D inhibitor, HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    afatinib + MRTX1133
    47
    Microtubule inhibitor, TROP-2-targeted antibody-drug conjugate
    LCB84
    48
    pan-RAF inhibitor, Src kinase inhibitor
    BAL3833
    49
    HDAC inhibitor, Arginine depleter
    panobinostat + pegargiminase
    50
    MEK inhibitor, mTOR inhibitor, mTORC2 inhibitor
    trametinib + Torin1
    51
    STAT3 inhibitor
    BBI608
    52
    DDX5 degrader
    FL118
    53
    EGFR inhibitor
    gefitinib
    54
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    55
    HER3 inhibitor
    MM-121
    56
    XPO1 inhibitor, KRAS G12C inhibitor
    sotorasib + selinexor
    57
    XPO1 inhibitor, KRAS inhibitor
    selinexor + MRTX1257
    58
    KRAS G12C inhibitor, Nicotinamide phosphoribosyltransferase inhibitor, PAK4 inhibitor
    sotorasib + KPT-9274
    59
    MYC inhibitor
    WB100
    60
    ERK2 inhibitor, PTPN11 inhibitor, ERK1 inhibitor
    ASN007 + ERAS-601
    61
    BET inhibitor, CDK4 inhibitor, CDK6 inhibitor
    palbociclib + JQ-1
    62
    SOS1 inhibitor, MEK inhibitor
    trametinib + BI-3406
    63
    KRAS G12D inhibitor, BET inhibitor, BRD4 degrader
    MRTX1133 + BI 894999 + dBET6
    64
    BET inhibitor, MEK inhibitor
    BI 894999 + LNP3794
    65
    MEK inhibitor
    IMM-6-415
    66
    KRAS Q61H inhibitor
    RMC-0708
    No biomarker
    KRAS wild-type
    KRAS G12R
    KRAS G12C
    KRAS mutation
    KRAS G12V
    KRAS G12
    KRAS G12D
    KRAS Q61H
    KRAS G12D + Chr del(9)(p21)
    MSI-L/dMMR
    MSI-H/dMMR
    PALB2 mutation
    CCL11 overexpression
    ATM mutation
    BRAF V600E
    PD-L1 expression
    BRAF V600
    PD-L1 overexpression
    TMB-H
    FASLG elevation
    TMB-L
    IL1RAP overexpression
    MUC1 underexpression
    BRCA1 mutation
    NRG1 fusion
    ATP1B1-NRG1 fusion
    APP-NRG1 fusion
    FGFR1 T141R
    PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L
    MSI-H/dMMR + TMB-H + PD-L1 overexpression
    BRCA1 mutation + TMB-H
    BRCA2 mutation
    MAP2K1 mutation
    MAP2K2 mutation
    PIK3CA mutation
    RNF43 mutation
    TP53 mutation + KRAS mutation
    KRAS mutation + PD-L1 expression
    ANGPT2-L
    LGALS1 elevation
    CCL4-L
    MUC16-L
    ARID1A mutation
    CHEK2 mutation
    MSI-H/dMMR + TMB-H
    C3M/PRO-C3 ratio elevation
    MSH2 mutation
    FANCF mutation
    BRCA1 mutation + BRCA2 mutation
    CLDN18.2 positive
    MUC1 overexpression
    DDR
    GLI1 expression
    SIRT1 overexpression
    BRCA mutation
    GATA6 expression
    CD276 expression
    SLC3A2-NRG1 fusion
    RAS mutation
    HGF elevation
    EGFR expression + MET expression
    MYC overexpression
    CAV1 overexpression
    CDKN2A deletion
    HRD
    GATA6 underexpression
    TROP2 expression
    TLE2 overexpression
    LAMC2 overexpression
    ANIB1 overexpression
    ASS1 underexpression
    TP53 mutation
    DDX5 overexpression